Craig-Hallum Maintains Buy on Phathom Pharmaceuticals, Raises Price Target to $17

Benzinga · 6d ago
Craig-Hallum analyst Chase Knickerbocker maintains Phathom Pharmaceuticals (NASDAQ:PHAT) with a Buy and raises the price target from $12 to $17.